期刊文献+

晚期肾癌的免疫治疗进展与述评 被引量:6

Progress and Comment on Immunotherapy of Advanced Renal Cell Carcinoma
下载PDF
导出
摘要 随着纳武单抗(Nivolumab)被写进晚期肾癌二线治疗指南,免疫治疗再次回到晚期肾癌的治疗领域并取得成功。免疫治疗单药一线治疗的疗效有限,因而免疫联合抗血管靶向治疗成为目前的主要进展。近年来,几项大型Ⅲ期随机对照研究先后公布研究结果。Nivolumab和伊匹单抗(Ipililmumab)的免疫联合免疫治疗推荐用于中高危晚期肾癌患者。免疫联合抗血管靶向治疗中帕博利珠单抗(Pembrolizumab)联合阿昔替尼(Axitinib)以及阿维鲁单抗(Avelumab)联合Axitinib也写入指南。如何选择免疫治疗的合适人群,需要结合疾病特征、危险分层和社会经济学综合考虑,并探索合适的生物预测标志物。 Immunotherapy has made great progress in the treatment of advanced renal cell carcinoma(RCC),since nivolumab was approved for the second-line therapy of advanced RCC.The efficacy of anti-PD1 monotherapy was limited in the first-line setting,therefore the combination of immunotherapy and anti-angiogenesis targeted therapy is becoming the trend.As the release of several randomized phaseⅢclinical trials results,ipilimumab in combination with nivolumab is recommended for intermediate-/highrisk advanced RCC.Pembrolizumab plus axitinib or avelumab plus axitinib are proved to be more efficacious than traditional targeted therapy.How to select the appropriate population for immunotherapy depends on individual characteristics,disease risk,social economics and appropriate prognostic biomarkers.
作者 周莉 盛锡楠 ZHOU Li;SHENG Xi’nan(Key Laboratory of Carcinogenesis and Translational Research,Ministry of Education,Department of Kidney Cancer and Melanoma,Peking University Cancer Hospital&Institute,Beijing 100142,China)
出处 《肿瘤防治研究》 CAS CSCD 2020年第3期149-153,共5页 Cancer Research on Prevention and Treatment
关键词 晚期肾癌 免疫治疗 生物标志物 Advanced renal cell carcinoma Immunotherapy Biomarker
  • 相关文献

同被引文献44

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部